Log on/register
BioMed Central home | Journals A-Z | Feedback | Support | My details

Email this article to a friend

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Nicolas M Furiak email, Haya Ascher-Svanum email, Robert W Klein email, Lee J Smolen email, Anthony H Lawson email, Robert R Conley email and Steven D Culler email

Cost Effectiveness and Resource Allocation 2009, 7:4doi:10.1186/1478-7547-7-4

Your name*
Your email address*
Recipient's email address*
(multiple email addresses should be separated with commas)
Email format
Please type your message into the box below:
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.